---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-002652"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2023-02-13T23:59:59+00:00"
generated_at: "2026-06-19T16:27:16.514643+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences raises $15.6M in public offering; believes it regains Nasdaq compliance

## Summary
- Gross proceeds of ~$15.6M from sale of 2.89M shares and pre-funded warrants, plus 6.45M warrants at $5.36 exercise price.
- Net proceeds of ~$14.1M to fund REVTx-100 and REVTx-300 development, including Phase 1a/1b studies and manufacturing.
- Company believes it now meets Nasdaq's $2.5M stockholders' equity requirement; bid price compliance at 9 of 10 consecutive days.
- Officers and directors subject to 90-day lock-up; institutional investors have leak-out limiting sales to 25% of trading volume until April 10.

## SEC filing metadata
- accession: 0000950170-23-002652
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2023-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017023002652/0000950170-23-002652-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017023002652/revb-20230209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-002652
- JSON: https://secwatch.observer/filing/0000950170-23-002652.json
- Plain text: https://secwatch.observer/filing/0000950170-23-002652.txt

## Key facts
- Material Agreements
  REVELATION BIOSCIENCES, INC. entered into Placement Agency Agreement with Roth Capital Partners, LLC valued at gross proceeds of approximately $15.6 million (effective 2023-02-09).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Roth Capital Partners, LLC
  - Value: gross proceeds of approximately $15.6 million
  - Effective: 2023-02-09
  source text: On February 9, 2023, Revelation Biosciences, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000095017023002652/0000950170-23-002652-index.htm
- Material Agreements
  REVELATION BIOSCIENCES, INC. entered into Purchase Agreement with certain purchasers valued at gross proceeds of approximately $15.6 million (effective 2023-02-09).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain purchasers
  - Value: gross proceeds of approximately $15.6 million
  - Effective: 2023-02-09
  source text: a securities purchase agreement (the “Purchase Agreement”) with certain purchasers for the purchase and sale, in a registered public offering by the Company (the “Public Offering”), of (i) an aggregate of 2,888,600 shares of its common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000095017023002652/0000950170-23-002652-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.